Project/Area Number |
04453153
|
Research Category |
Grant-in-Aid for General Scientific Research (B)
|
Allocation Type | Single-year Grants |
Research Field |
Chemical pharmacy
|
Research Institution | KYOTO UNIVERSITY |
Principal Investigator |
SUGIURA Yukio Institute for Chemical Research Kyoto University, Professor, 化学研究所, 教授 (40025698)
|
Project Period (FY) |
1992 – 1993
|
Project Status |
Completed (Fiscal Year 1993)
|
Budget Amount *help |
¥8,000,000 (Direct Cost: ¥8,000,000)
Fiscal Year 1993: ¥2,200,000 (Direct Cost: ¥2,200,000)
Fiscal Year 1992: ¥5,800,000 (Direct Cost: ¥5,800,000)
|
Keywords | enediyne / DNA cleavage / antitumor activity / esperamicin / calicheamicin / dynemicin / DNA conformation / molecular design / エスペラミシン / RNA切断 / コンホメーション選択的切断 / カリケミシン / C-1027 / DNA認識 / ビラジカル |
Research Abstract |
Enediyne antitumor antibiotics show novel molecular structures, afascinating action mode, and potent DNA cleaving activity. We clarified some characteristics of DNA strand scission by enediyne antibiotics such as esperamicin A_1, calicheamicin gamma_1 and dynemicin A. (1) Double-stranded cleavage fashion : Of special interest is the fact that neocarzinostatin and C-1027 causes strand breaks two base pairs at specific sites in the two strands. This novel double-stranded cleavage fashion is different from that of esperamicin A_1 and calicheamicin gamma_1, which are found to have a three-bpseparation between cleavage sites on the two strands. (2) Sequence-specific cleavage mode : Esperamicin A_1 and calicheamicin gamma_1 cleaved specifically at 5'-AGGA/TCCT sequences. (3) Conformation-selective strand break : The cleavage sites by dynemicin A are observed at nucleotide residues near the bulge, mismatch, or nick sites. The result demonstrates conformation-dependence of DNA cleavage by dynemicin antibiotics. These informations provide valuable implications for biological action of enediyne antitumor antibiotics and for molecular disign of new enediyne compounds.
|
Report
(3 results)
Research Products
(17 results)